Business Wire

GCCA Concrete in Life Global Photography Competition Launches

19.9.2025 14:00:00 CEST | Business Wire | Press Release

Share

This year’s Concrete in Life, a popular global photography competition which celebrates the essential role of concrete across the world, has been officially launched. Now in its 7th year, the competition which receives tens of thousands of entries every year from every corner of the world, highlights the sustainability, versatility, beauty and durable presence of the world’s most used material after water.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919202417/en/

Overall Winner, Concrete in Life 2024/25, Venice Beach Skating by Henrik Hagerup, Venice Beach, Los Angeles, USA

Run by the Global Cement and Concrete Association (GCCA), the competition is open to everyone - professionals, amateurs, or anyone with a smart phone, and entry to the competition is free.

Contestants will have a chance to win the crown with a top prize of $10,000 prize money for Best Overall Concrete in Life photo, while each category winner will receive $2,500.

Thomas Guillot, GCCA Chief Executive and one of the competition judges, said: “Concrete is essential to our lives, building our roads, bridges, houses and the cities we live in. Its innate properties of strength and versatility have led it to create some of the best and most beautiful architecture and infrastructure of our time. Our Concrete in Life photography competition gives people the chance to capture the beauty of concrete and show what it means to them.”

Contestants are invited to submit their pictures posting on their social media accounts and tagging the competition #ConcretInLife2526 and one the following categories.

  • #UrbanConcrete – images of the city landscapes and buildings around us, both well-known and hidden away
  • #ConcreteInfrastructure – photographs of the infrastructure that enables our world, in our cities and rural, above and below ground
  • #ConcreteInDailyLife – the human side of concrete and how it’s used and interacted with daily
  • #ConcreteBeautyAndDesign – capturing the beauty of concrete, showing how it’s used in a particularly striking visual way, whether at a large or small scale

Rajneesh Khattar- Senior Group Director, World of Concrete and competition judge, said: "Concrete is everywhere and its impact on our everyday lives is hard to ignore. With construction being the art of making a meaningful whole out of many parts, it’s time to appreciate the aesthetic and architectural appeal of concrete besides its versatile applications, immense strength and durability."

Chris George - Content Director, Digital Camera World and longstanding competition judge, said: “Concrete is all around us and has a beauty that might not always be obvious to some people. The Concrete in Life global photography competition continues to prove it is possible to take stunning shots of architecture and the manmade environment that show off the beauty of this universal building material.”

The competition is open until 30 November 2025, with the winners announced in early 2026. For more details of the competition and for photos from previous years, please visit https://gccassociation.org/concreteinlife.

Mr Guillot added: “We’ve received over 20,000 photos from both professional and amateur photographers every year for the last few years and look forward to receiving even more inspiring entries this year.”

Images of previous years available here.

About the GCCA: The GCCA and its members account for the majority of global cement production capacity outside of China, as well as a growing number of Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete. Through the launch of its Roadmap in 2021, cement and concrete became the first global essential industry to commit to delivering net zero CO2 emissions by 2050.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250919202417/en/

Contacts

Media enquiries: paul.adeleke@gccassociation.org

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye